Close Menu

NEW YORK – Results presented during the European Lung Cancer Virtual Congress this week demonstrated that 45 percent of 51 evaluable non-small cell lung cancer patients treated with Mirati Therapeutics' investigational KRAS G12C inhibitor adagrasib exhibited partial responses to the treatment, and 24 patients had stable disease. The results are from Mirati's multi-cohort Phase I/II KRYSTAL-1 study, which evaluated adagrasib as a treatment for 79 advanced NSCLC patients whose tumors harbored KRAS G12C mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.